We’re pleased to share that Perspective Therapeutics will take part in a Fireside Chat at the @UBS Global Healthcare Conference today from 4:15–4:50 p.m. ET in Palm Beach, FL. Sign in here to watch the webcast: https://t.co/CthAO36fAl $CATX

Perspective provided recent business highlights and reported 3Q25 results. We shared clinical updates on [212-Pb]VMT-α-NET at the #ESMO25, NANETS, and Triple meetings, and we continue to advance our pipeline of targeted #radiopharmaceuticals. For more: https://t.co/dGQceT9yiR

Get speeds up to 400+ Mbps for frequent video calls—even when multiple people in your household are online. Order online in under 2 minutes.

Perspective Therapeutics is attending the Truist Securities BioPharma Symposium today in New York City! Our team looks forward to connecting through 1x1 meetings to discuss our advancing radiopharmaceutical pipeline and upcoming milestones. $CATX For more: https://t.co/xJKC6yNplG

Perspective senior management will participate in two investor conferences in November. Check our newsroom for more details -> https://t.co/xJKC6yNplG

Updated interim data presented at #ESMO25 from our ongoing [212Pb]VMT-α-NET trial showed a compelling overall profile. $CATX https://t.co/HpETFbIEwg

Save the date! Perspective Therapeutics to provide recent business highlights and report 3Q financial results on November 10: https://t.co/bRwIGLEd6Q $CATX

Earlier today, Perspective presented updated interim results from its Phase 1/2a study of [212Pb]VMT-α-NET at #ESMO25. There will be a conference call today to discuss the data at 8:30AM ET. For more details on the presentation and conference call: https://t.co/HpETFbJclO $CATX

We are on the ground at the European Society for Medical Oncology Congress 2025 (#ESMO25) in Berlin, Germany! We will be presenting updated interim results from our Phase 1/2a study of [212Pb]VMT-α-NET on Monday, Oct. 20 at 8:58AM CEST. For more: https://t.co/gDj5lt3lDi $CATX

We’re proud to be featured in @PharmaNowGlobal highlighting the first patient has been dosed in a new cohort of our Phase 1/2a trial, exploring [212Pb]VMT01 in combination with a PD-1 inhibitor. For more details: https://t.co/LvGIVnaJ2g $CATX #TargetedAlphaTherapy #oncology

Our team is on the ground at #EANM2025 this weekend in Barcelona, where we’ll be presenting several posters and connecting with global experts in nuclear medicine and radiopharmaceutical development. For more details: https://t.co/hBdXz47H5e $CATX

Perspective has announced the first patient was treated with [212Pb]PSV359 in the second cohort of the Company’s Phase 1/2a study in patients with FAP-alpha positive solid tumors. To learn more: https://t.co/0zECw70Exe $CATX

Our team will be at #EANM2025 in Barcelona this weekend presenting posters on FAP directed theranostics approach, Pb-212 alpha therapy and EBRT in neuroendocrine spheroids, SPECT imaging of Pb-212, and chelator design for Ac-225. For more details: https://t.co/hBdXz47H5e $CATX

CEO Thijs Spoor sat down with Rx for Biotech host Chris Leidli to discuss the future of #radiopharma, and the infrastructure, strategy, and innovation required to bring targeted cancer therapies from concept to clinic. Listen to the episode here: https://t.co/1uv14qnVRI $CATX

The FDA’s new draft guidance marks a pivotal moment for the radiopharmaceutical space. This @BioSpace article featuring Perspective captures its significance as a strong signal that radiopharma is poised to transform how we treat cancer. Read here: https://t.co/AtryR0PCo4 $CATX

Earlier this week, Perspective announced the first patient was treated with [212Pb]VMT01 at 3.0 mCi in combination with nivolumab in its ongoing Phase 1/2a study of MC1R-Positive metastatic melanoma. To learn more: https://t.co/bKoZlEEMsp $CATX

We’ve been featured in this @BioSpace article, which highlights how we’ve leveraged Washington’s teeming life sciences ecosystem and unique locational advantages. Hear from our CEO, Thijs Spoor, on why he moved Perspective’s HQ to Seattle here: https://t.co/10TU1rGPrI $CATX

Perspective senior management will be attending the OPCO Targeted Radiopharmaceutical Therapies in Oncology Summit tomorrow in NYC. You can find us participating in two panel discussions. Visit our newsroom for more details: https://t.co/NwfOy7xDeq $CATX

Perspective senior management will be attending the Morgan Stanley 23rd Annual Global Healthcare Conference today in NYC. Visit our newsroom for more details: https://t.co/NwfOy7xDeq $CATX

Join us in welcoming Joel Sendek to Perspective Therapeutics as our new CFO! He brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at several leading firms. $CATX Learn more: https://t.co/InbPPj2KAZ

Perspective senior management will participate in three investor conferences in September. Check our newsroom for more details -> https://t.co/NwfOy7xDeq